Pharmacological Management of Chronic Neuropathic Pain – Consensus Statement and Guidelines from the Canadian Pain Society
Authors:
Top Cited Papers
Open Access
- 1 January 2007
- journal article
- review article
- Published by Wiley in Pain Research and Management
- Vol. 12 (1) , 13-21
Abstract
Neuropathic pain (NeP), generated by disorders of the peripheral and central nervous system, can be particularly severe and disabling. Prevalence estimates indicate that 2% to 3% of the population in the developed world suffer from NeP, which suggests that up to one million Canadians have this disabling condition. Evidence‐based guidelines for the pharmacological management of NeP are therefore urgently needed. Randomized, controlled trials, systematic reviews and existing guidelines focusing on the pharmacological management of NeP were evaluated at a consensus meeting. Medications are recommended in the guidelines if their analgesic efficacy was supported by at least one methodologically sound, randomized, controlled trial showing significant benefit relative to placebo or another relevant control group. Recommendations for treatment are based on degree of evidence of analgesic efficacy, safety, ease of use and cost‐effectiveness. Analgesic agents recommended for first‐line treatments are certain antidepressants (tricyclics) and anticonvulsants (gabapentin and pregabalin). Second‐line treatments recommended are serotonin noradrenaline reuptake inhibitors and topical lidocaine. Tramadol and controlled‐release opioid analgesics are recommended as third‐line treatments for moderate to severe pain. Recommended fourth‐line treatments include cannabinoids, methadone and anticonvulsants with lesser evidence of efficacy, such as lamotrigine, topiramate and valproic acid. Treatment must be individualized for each patient based on efficacy, side‐effect profile and drug accessibility, including cost. Further studies are required to examine head‐to‐head comparisons among analgesics, combinations of analgesics, long‐term outcomes, and treatment of pediatric and central NeP.Keywords
Funding Information
- Pfizer
This publication has 60 references indexed in Scilit:
- A Double-Blind, Randomized Multicenter Trial Comparing Duloxetine with Placebo in the Management of Diabetic Peripheral Neuropathic PainPain Medicine, 2005
- Duloxetine vs. placebo in patients with painful diabetic neuropathyPain, 2005
- Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled studyPain, 2004
- Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trialBMJ, 2004
- Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathyPain, 2003
- Selective Serotonin Reuptake Inhibitors and CNS Drug InteractionsClinical Pharmacokinetics, 1997
- The d- and l- isomers of methadone bind to the non-competitive site on the N-methyl-d-aspartate (NMDA) receptor in rat forebrain and spinal cordNeuroscience Letters, 1997
- A systematic review of antidepressants in neuropathic painPain, 1996
- Response to intravenous lidocaine infusion predicts subsequent response to oral mexiletine: A prospective studyJournal of Pain and Symptom Management, 1996
- Transdermal clonidine compared to placebo in painful diabetic neuropathy using a two-stage ‘enriched enrollment’ designPain, 1995